These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28977114)

  • 21. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
    Gies N; Kroeker KI; Wong K; Fedorak RN
    Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
    Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
    Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience.
    Oussalah A; Laclotte C; Chevaux JB; Bensenane M; Babouri A; Serre AA; Boucekkine T; Roblin X; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2008 Oct; 28(8):966-72. PubMed ID: 18652603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis.
    Burness CB; Keating GM
    BioDrugs; 2013 Jun; 27(3):247-62. PubMed ID: 23580096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.
    McDermott E; Murphy S; Keegan D; O'Donoghue D; Mulcahy H; Doherty G
    J Crohns Colitis; 2013 Mar; 7(2):150-3. PubMed ID: 22520592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
    Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
    Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
    J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    Suzuki Y; Motoya S; Hanai H; Hibi T; Nakamura S; Lazar A; Robinson AM; Skup M; Mostafa NM; Huang B; Thakkar R; Watanabe M
    J Gastroenterol; 2017 Sep; 52(9):1031-1040. PubMed ID: 28321512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.
    Wolf D; D'Haens G; Sandborn WJ; Colombel JF; Van Assche G; Robinson AM; Lazar A; Zhou Q; Petersson J; Thakkar RB
    Aliment Pharmacol Ther; 2014 Sep; 40(5):486-97. PubMed ID: 25041859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Baert F; Vande Casteele N; Tops S; Noman M; Van Assche G; Rutgeerts P; Gils A; Vermeire S; Ferrante M
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1324-32. PubMed ID: 25277873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis.
    Kumei S; Sakurai T; So S; Itaba S; Akiho H; Nakamura S; Kim H; Yamasaki M; Takatsu N; Maekawa R; Sakemi R; Watanabe T; Shibata M; Kume K; Yoshikawa I; Takaki Y; Harada M
    Intern Med; 2021 Dec; 60(24):3849-3856. PubMed ID: 34121007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
    Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
    J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
    Zhang ZM; Li W; Jiang XL
    Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
    Afif W; Leighton JA; Hanauer SB; Loftus EV; Faubion WA; Pardi DS; Tremaine WJ; Kane SV; Bruining DH; Cohen RD; Rubin DT; Hanson KA; Sandborn WJ
    Inflamm Bowel Dis; 2009 Sep; 15(9):1302-7. PubMed ID: 19408340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Roblin X; Bigard MA
    World J Gastroenterol; 2007 Apr; 13(16):2328-32. PubMed ID: 17511032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.